Skip to main content

Advertisement

SpringerLink
Log in

Differential effectiveness of a range of novel drug-resistance modulators, relative to verapamil, in influencing vinblastine or teniposide cytotoxicity in human lymphoblastoid CCRF-CEM sublines expressing classic or atypical multidrug resistance

  • Original Articles
  • Verapamil, Vinblastine, Teniposide, CCRF-CEM, Cytotoxicity, Multidrug Resistance
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

A series of five potential modulators of resistance were tested for their relative ability, as compared with verapamil, to sensitize CEM lymphoblastoid leukemia drug-resistant tumor sublines expressing either the classic or the atypical multidrug-resistance (MDR) phenotype to vinblastine or teniposide. Maximal non-cytotoxic concentrations of each modulator were tested and sensitization indices (SIs) were derived by comparing the drug concentration required to inhibit growth by 50% in their presence or absence. Like verapamil (10 μM) itself, three of the other modulators tested, namely, S9788 (4 μM), flunarizine (20 μM) and quinidine (30 μM), resulted in 2-to 3-fold sensitization of vinblastine against the parental CEM cells, and comparable effects were noted in the CEM/VM-1 cells, which were not cross-resistant to vinblastine. In contrast, cyclosporin A (0.5 μM) and B859-35 (2 μM) did not enhance vinblastine growth inhibition in these lines. However, the greatest sensitization with all the modulators was noted in the classic MDR VBL 1000 cells, with SIs ranging from 40- to 350-fold, except for cyclosporin A, which proved ineffective at the concentration tested (SI, 2.6). The greatest extent of differential sensitization of these VBL1000 tumor cells occurred with quinidine or B859-35, which proved significantly more effective than verapamil alone. Combinations of modulators resulted in additive effects, with B859-35 plus cyclosporin A proving superior to B859-35 plus verapamil. In contrast, none of these compounds proved effective as a sensitizer to teniposide. The growth-inhibitory effects of this drug were not modified significantly in either the 92-fold teniposideresistant VM-1 cells or in the parental cells. Addition of verapamil itself also failed to modulate teniposide growth inhibition in the VBL1000 cells, which express significant cross-resistance to this drug (36-fold). However, SI values of 3- to 5-fold were obtained using quinidine or B859-35. These results serve (a) to emphasise the need to monitor the effects of modulators not only on drug-resistant cells but also on their drug-sensitive counterparts so as to ensure differential sensitization such that normal sensitive tissues are not likely to be adversely influenced and (b) to highlight the observation that the extent of modulation differs depending not only on the antitumor drug used but also on the mechanism of drug resistance expressed. This in vitro model system appears to provide a useful screening system for resistance modulators and certainly could be used in attempts to identify alternative agents that may influence teniposide sensitivity in these drug-resistant sublines.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Akiyama SI, Cornwell MM, Kuwano M, Pastan I, Gottesman MM (1988) Most drugs that reverse multidrug resistance also inhibit photoaffinity labelling of P-glycoprotein by a vinblastine analog. Mol Pharmacol 33: 144–147

    Google Scholar 

  2. Barrand MA, Rhodes T, Center MS, Twentyman PR (1993) Chemosensitisation and drug accumulation effects of cyclosporin A, PSC-833 and verapamil in human MDR large cell lung cancer cells expressing a 190k membrane protein distinct from P-glycoprotein. Eur J Cancer 29 A: 408–415

    Google Scholar 

  3. Beck WT (1991) Modulators of B-glycoprotein-associated multidrug resistance. In: Ozols RF (eds) Molecular and clinical advances in anticancer drug resistance. Kluwer, Boston, pp 151–170

    Google Scholar 

  4. Beck WT, Cirtain MC, Danks MK, Felsted RL, Safa AR, Wolverton JS, Suttle DP, Trent JM (1987) Pharmacological, molecular, and cytogenetic analysis of “atypical” multidrug-resistant human leukemic cells. Cancer Res 47: 5455–5460

    Google Scholar 

  5. Beck WT, Cirtain MC, Look AT, Ashmun RA (1986) Reversal of vinca alkaloid resistance but not multiple drug resistance in human leukemic cells by verapamil. Cancer Res 46: 778–784

    Google Scholar 

  6. Bellamy WT, Dalton WS, Kailey JM, Gleason MC, McCloskey TM, Door RT, Alberts DS (1988) Verapamil reversal of doxorubicin resistance in multidrug-resistant human myeloma cells and association with drug accumulation and DNA damage. Cancer Res 48: 6303–6308

    Google Scholar 

  7. Boesch D, Gaveriaux C, Jachez B, Pourtier-Manzanedo A, Bollinger P, Loor F (1991) In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res 51: 4226–4233

    Google Scholar 

  8. Bradley G, Juranka PF, Ling V (1988) Mechanisms of multidrug resistance. Biochim Biophys Acta 948: 87–128

    Google Scholar 

  9. Chambers SK, Hait WN, Kacinski BM, Keyes SR (1989) Enhacement of anthracycline growth inhibition in parent and multidrug-resistant Chinese hamster ovary cells by cyclosporin A and its analogues. Cancer Res 49: 6725–6729

    Google Scholar 

  10. Cole SPC, Downes HF, Slovak ML (1989) Effect of calcium antagonists on the chemosensitivity of two multidrug-resistant human tumour cell lines which do not overexpress P-glycoprotein. Br J Cancer 59: 42–46

    Google Scholar 

  11. Coon JS, Knudson W, Clodfelter K, Lu B, Weinstein RS (1991) Solutol HS 15, nontoxic polyoxyethylene esters of 12-hydroxystearic acid, reverses multidrug resistance. Cancer Res 51: 897–902

    Google Scholar 

  12. Danks MK, Schmidt CA, Cirtain MC, Suttle DP, Beck WT (1988) Altered catalytic activity of and DNA cleavage by DNA topoisemcrase II from human leukemic cells selected for resistance to VM-26. Biochemistry 27: 8861–8869

    Google Scholar 

  13. Danks MK, Yalowich JC, Beck WT (1987) Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide. Cancer Res 47: 1297–1301

    Google Scholar 

  14. Foley GE, Lazarus H, Farber S, Uzman BG, Boone BA, McCarthy RE (1965) Continuous culture of human lymphoblasts from peripheral blood of a child with acute leukemia. Cancer 18: 522–529

    Google Scholar 

  15. Ford JM, Hait WN (1990) Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42: 155–159

    Google Scholar 

  16. Georges E, Sharom FJ, Ling V (1990) Multidrug resistance and chemosensitization: therapeutic implications for cancer chemotherapy. Adv Pharmacol 21: 185–220

    Google Scholar 

  17. Gerlach JH, Bell DR, Karakousis C, Slocum HK, Kartner N, Rustum YM, Ling V, Baker RM (1987) P-glycoprotein in human sarcoma: evidence for multidrug resistance. J Clin Oncol 5: 1452–1460

    Google Scholar 

  18. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai S-L, Gazdar A, Pirker R, Green JA, Crist W, Brodeur GM, Lieder M, Cossman J, Gottesman MM, Pastan I (1989) Expression of multidrug resistance gene in human cancers. J Natl Cancer Inst 81: 116–124

    Google Scholar 

  19. Gottesman MM, Pastan I (1989) Clinical trials of agents that reverse multidrug resistance. J Clin Oncol 7: 409–410

    Google Scholar 

  20. Hill BT, Graaf WTA van der, Hosking LK, Vries EGE de, Mulder NH, Whelan RDH (1993) Evaluation of S9788 as a potential modulator of drug resistance against human tumour sublines expressing differing resistance mechanisms in vitro. Int J Cancer (in press)

  21. Hofmann J, Ueberall F, Egle A, Grunicke H (1991) B-859-35, a new drug with anti-tumor activity reverses multi-drug resistance. Int J Cancer 47: 870–874

    Google Scholar 

  22. Holzmayer TA, Hilsenbeck S, Von Hoff DD, Roninson IB (1992) Clinical correlates ofmdr 1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J Natl Cancer Inst 84: 1486–1491

    Google Scholar 

  23. Hosking LK, Hendriks H, Hill BT (1992) In vitro evaluation of the enhancement of vinblastine cytotoxicity using a panel of novel modulators. Br J Cancer 65 (Suppl XVI): 21

    Google Scholar 

  24. Hu XF, Martin TJ, Bell DR, Luise M de, Zalcberg JR (1990) Combined use of cyclosporin A and verapamil in modulating multidrug resistance in human leukemia cell lines. Cancer Res 50: 2953–2957

    Google Scholar 

  25. Ishida Y, Shimada Y, Shimoyama M (1990) Synergistic effect of cyclosporin A and verapamil in overcoming vincristine resistance of multidrug-resistant cultured human leukemia cells. Jpn J Cancer Res 81: 834–841

    Google Scholar 

  26. Kartner N, Everden-Porelle D, Bradley G, Ling V (1985) Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature 316: 820–823

    Google Scholar 

  27. Kavallaris M, Madafiglio J, Norris MD, Haber M (1993) Resistance to tetracycline, a hydrophilic antibiotic, is mediated by P-glycoprotein in human multidrug-resistant cells. Biochem Biophys Res Commun 190: 79–85

    Google Scholar 

  28. Klohs WD, Steinkampf RW, Havlick MJ, Jackson RC (1986) Resistance to anthrapyrazoles and anthracyclines in multidrug resistant P388 murine leukemia cells: reversal by calcium blockers and calmodulin antagonists. Cancer Res 46: 4352–4356

    Google Scholar 

  29. Larsson R, Nygren P (1990) Pharmacological modification of multidrug resistance (MDR) in vitro detected by a novel fluorometric microculture cytotoxicity assay. Reversal of resistance and selective cytotoxic actions of cyclosporin A and verapamil on MDR leukemia T-cells. Int J Cancer 46: 67–72

    Google Scholar 

  30. Lehnert M, Dalton WS, Roe D, Emerson S, Salmon SE (1991) Synergistic inhibition by verapamil and quinine of P-glycoprotein-mediated multidrug resistance in a human myeloma cell line model. Blood 77: 348–354

    Google Scholar 

  31. Meijer C, Mulder NH, Timmer-Bosscha H, Peters WHM, Vries EGE de (1991) Combined in vitro modulation of Adriamycin resistance. Int J Cancer 49: 582–586

    Google Scholar 

  32. Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, Salmon SE (1991) P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 9: 17–24

    Google Scholar 

  33. Naito M, Tsuge H, Kuroko C, Koyama T, Tomida A, Tatsuta T, Heike Y, Tsuruo T (1993) Enhancement of cellular accumulation of cyclosporine by anti-P-glycoprotein monoclonal antibody MRK-16 and synergistic modulation of multidrug resistance. J Natl Cancer Inst 85: 311–316

    Google Scholar 

  34. Nygren P, Larsson R (1991) Differential in vitro sensitivity of human tumor and normal cells to chemotherapeutic agents and resistance modulators. Ann Oncol 2: 305–306

    Google Scholar 

  35. Osann K, Sweet P, Slater LM (1992) Synergistic interaction of cyclosporin A and verapamil on vincristine and daunorubicin resistance in multidrug-resistant human leukemia cells in vitro. Cancer Chemother Pharmacol 30: 152–154

    Google Scholar 

  36. Pennock GD, Dalton WS, Roeske WR, Appleton CP, Mosley K, Plezia P, Miller TP, Salmon SE (1991) Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration. J Natl Cancer Inst 83: 105–110

    Google Scholar 

  37. Pierré A, Dunn TA, Kraus-Berthier L, Léonce S, Saint-Dizier D, Régnier G, Dhainaut A, Berlion M, Bizzari J-P, Atassi G (1992) In vitro and in vivo circumvention of multidrug resistance by Servier 9788, a novel triazinoaminopiperidine derivative. Invest N Drugs 10: 137–148

    Google Scholar 

  38. Ramu A, Glaubiger D, Fuks Z (1984) Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by tamoxifen and other triparanol analognes. Cancer Res 44: 4392–4395

    Google Scholar 

  39. Ramu A, Ramu N (1992) Reversal of multidrug resistance by phenothiazines and structurally related compounds. Cancer Chemother Pharmacol 30: 165–173

    Google Scholar 

  40. Safa Ar (1993) Photoaffinity labeling of P-glycoprotein in multidrug-resistant cells. Cancer Invest 11: 46–56

    Google Scholar 

  41. Salmon SE, Dalton WS, Grogan TM, Plezia P, Lehnert M, Roe DJ, Miller TP (1991) Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. Blood 78: 44–50

    Google Scholar 

  42. Sehested M, Friche E, Jensen PB, Demant EJF (1992) Relationship of VP-16 to the classical multidrug resistance phenotype. Cancer Res 52: 2874–2879

    Google Scholar 

  43. Slater LM, Murray SL, Wetzel MW, Sweet P, Stupecky M (1986) Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro. J Clin Invest 77: 1405–1408

    Google Scholar 

  44. Slovak ML, Hoeltge GA, Dalton WS, Trent JM (1988) Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines. Cancer Res 48: 2793–2797

    Google Scholar 

  45. Sonneveld P, Durie BGM, Lokhorst HM, Marie J-P, Solbu G, Suciu S, Zittoun R, Lowenberg B, Nooter K (1992) Modulation of multidrug-resistant multiple myeloma by cyclosporin. Lancet 340: 255–259

    Google Scholar 

  46. Stallard S, Kaye SB (1989) Reversal of resistance in the breast cancer cell line MCF-7 ADR was most effective with the modulating agent quinidine. Br J Cancer 60: 500

    Google Scholar 

  47. Tsuruo T (1991) Reversal of multidrug resistance by calcium channel blockers and other agents. In: Roninson IB (ed) Molecular and cellular biology of multidrug resistance in tumor cells. Plenum, New York, pp 349–372

    Google Scholar 

  48. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y (1981) Overcoming of vincristine resistance in P388 leukemia in vivo and intro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41: 1967–1972

    Google Scholar 

  49. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y (1982) Increased accumulation of vincristine and Adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res 42: 4730–4733

    Google Scholar 

  50. Tsuruo T, Iida H, Kitatani Y, Yokota K, Tsukagoshi S, Sakurai Y (1984) Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and Adriamycin in drug-resistant tumor cells. Cancer Res 44: 4303–4307

    Google Scholar 

  51. Twentyman P, Fox N, Bleehan N (1987) Drug resistance in human lung-cancer cell lines: cross-resistance studies and effects of the calcium channel transport blocker, verapamil. Int J Radiat Oncol Biol Phys 12: 1355–1360

    Google Scholar 

  52. Twentyman PR (1992) Cyclosporins as drug resistance modifiers. Biochem Pharmacol 43: 109–117

    Google Scholar 

  53. Twentyman PR, Reeve JG, Koch G, Wright KA (1990) Chemosensitisation by verapamil and cyclosporin A in mouse tumour cells expressing different levels of P-glycoprotein and CP22 (sorein). Br J Cancer 62: 89–95

    Google Scholar 

  54. Bliek AM van der, Borst P (1989) Multidrug resistance. Adv Cancer Res 52: 165–203

    Google Scholar 

  55. Graaf WTA van der, Vries EGE de, Uges DRA, Nanninga AG, Vellenga E, Mulder POM, Mulder NH (1991) In vitro and in vivo modulation of multi-drug resistance with amiodarone. Int J Cancer 48: 616–622

    Google Scholar 

  56. Warr JR, Brewer F, Anderson M, Fergusson J (1986) Verapamil hypersensitivity of vincristine-resistant Chinese ovary cell lines. Cell Biol Int Rep 10: 389–399

    Google Scholar 

  57. Willingham MC, Cornwell MM, Cardarelli CO, Gottesman MM, Pastan I (1986) Single cell analysis of daunomycin uptake and efflux in multidrug-resistant and-sensitive KB cells: effects of verapamil and other drugs. Cancer Res 46: 5941–5946

    Google Scholar 

  58. Wishart GC, Plumb JA, Morrison JG, Hamilton TG, Kaye SB (1992) Adequate tumour quinidine levels for multidrug resistance modulation can be achieved in vivo. Eur J Cancer 28: 28–31

    Google Scholar 

  59. Yang C-PH, Greenberger LM, Horwitz SB (1991) Reversal of multi-drug resistance in tumor cells. In: Chou T-C, Rideout DC (eds) Synergism and antagonism in chemotherapy. Academic Press, London, pp 311–338

    Google Scholar 

  60. Yang CH, DePinho SG, Greenberger LM, Arceci RH, Horwitz SB (1989) Progesterone interacts with P-glycoprotein in multidrug-resistant cells and in the endometrium of gravid uterus. J Biol Chem 264: 782–788

    Google Scholar 

  61. Zamora JM, Beck WT (1986) Chloroquine enhancement of anticancer drug cytotoxicity in multiple drug resistant human leukemic cells. Biochem Pharmacol 35: 4303–4310

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cellular Chemotherapy Laboratory, Imperial Cancer Research Fund, 44 Lincoln's Inn Fields, WC2A 3PX, London, UK

    Bridget T. Hill (Directeur de la Divison Cancerologie)

  2. Centre de Recherche Pierre Fabre, 17, avenue Jean Moulin, F-81106, Castres Cedex, France

    Louise K. Hosking

Authors
  1. Bridget T. Hill
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Louise K. Hosking
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hill, B.T., Hosking, L.K. Differential effectiveness of a range of novel drug-resistance modulators, relative to verapamil, in influencing vinblastine or teniposide cytotoxicity in human lymphoblastoid CCRF-CEM sublines expressing classic or atypical multidrug resistance. Cancer Chemother. Pharmacol. 33, 317–324 (1994). https://doi.org/10.1007/BF00685907

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00685907

Keywords

Search

Navigation